Adding CD28 costimulation to cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term cytotoxicity ...
WTX212, an erythrocyte-anti-PD1 antibody conjugate, to demonstrate anti-tumor activities in tumor models and patients with cancer with acquired resistance to immunotherapy. The SPEARHEAD-1 trial of ...
This is a preview. Log in through your library . Abstract Programmed cell death–1 (PD-1)–targeted therapies enhance T cell responses and show efficacy in multiple cancers, but the role of ...
With analysts looking for a meaningful increase in the number of responses for Regeneron's phase 1/2 solid tumor trial, a fresh data slice shows just one complete response across 94 patients.
This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include a full text component.
The collaboration will combine Rondo’s proprietary CD28 co-stimulatory platform with Lilly’s drug development and commercialization expertise to develop co-stimulatory bispecific antibodies to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results